Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2021-04-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
联合资信评估股份有限公司关于终止“18瑞康01”信用等级的公告
Regulatory Filings
2021-04-22 Chinese
2018年面向合格投资者公开发行公司债券（第一期）“18瑞康01”2021年本息兑付暨摘牌公告
Delisting Announcement Classification · 95% confidence The document is an official announcement from 瑞康医药集团股份有限公司 regarding the maturity, interest payment, and delisting (摘牌) of a corporate bond issued in 2018 ("18 瑞康 01"). It details the bond's final trading day, interest payment date, principal repayment date, and the bond's delisting date from the Shenzhen Stock Exchange. The document includes bond terms, payment instructions, tax information, and contact details. It is not a financial report or audit but a formal notice about bond redemption and delisting. Given the focus on bond maturity and delisting, the document fits best under the category of Delisting Announcement (DLST). The document length is 4415 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the classification is DLST with high confidence.
2021-04-15 Chinese
瑞康医药集团股份有限公司关于收到《中国证监会行政许可申请终止审查通知书》的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the company 瑞康医药集团股份有限公司 regarding the termination of the review process by the China Securities Regulatory Commission (中国证监会) for the company's non-public issuance of A shares. It references a board meeting decision to terminate the 2020 non-public stock issuance and withdraw the application materials. The document is short (641 characters) and serves as a regulatory announcement about the status of a capital raising application, not a detailed financial report or full filing. It does not contain financial statements or detailed analysis but rather informs about the cessation of a capital market activity and regulatory approval process. Therefore, it fits best under Capital/Financing Update (CAP).
2021-04-09 Chinese
内部控制规则落实自查表
Governance Information Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to audit operations, information disclosure, insider trading controls, fundraising, related party transactions, external guarantees, major investments, and other important matters. It also mentions changes in independent directors and their supervisory activities. The document is a self-assessment or internal control checklist rather than a financial report, earnings release, or regulatory announcement. It does not contain financial statements or earnings data, nor is it a notice or announcement of a report. It is a detailed internal control and governance-related document, which fits best under Governance Information (CGR). The document length is under 5,000 characters, but it is substantive and not merely an announcement. Therefore, the classification is CGR with high confidence.
2021-03-30 Chinese
关于举办2020年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about hosting the 2020 annual performance explanation meeting (业绩说明会), which is a type of earnings or performance presentation event. It references the 2020 annual report already published on March 31, 2021, and invites investors to participate in an online meeting on April 8, 2021. The document does not contain actual financial statements or detailed financial data but rather serves as a notice for the upcoming earnings explanation session. According to the filing definitions, such announcements about performance explanation meetings are best classified as Investor Presentation (IP) since they focus on financials, strategy, and market position presented to investors. The document length is short and it is not the report itself, so it is not an Annual Report (10-K) or Earnings Release (ER).
2021-03-30 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2021-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.